Potential therapeutic impact of omega-3 long chain-polyunsaturated fatty acids on inflammation markers in Duchenne muscular dystrophy: A double-blind, controlled randomized trial
Por:
Rodríguez-Cruz M., Cruz-Guzmán O.D.R., Almeida-Becerril T., Solís-Serna A.D., Atilano-Miguel S., Sánchez-González J.R., Barbosa-Cortés L., Ruíz-Cruz E.D., Huicochea J.C., Cárdenas-Conejo A., Escobar-Cedillo R.E., Yam-Ontiveros C.A., Ricárdez-Marcial E.F.
Publicada:
1 ene 2018
Resumen:
Background & aims: Duchenne Muscular Dystrophy (DMD) is the most frequent dystrophy in childhood generated by a deficiency in dystrophin. DMD is a neuromuscular disease and its clinical course comprises chronic inflammation and gradual muscle weakness. Supplementation of omega-3 long chain-Polyunsaturated Fatty Acids (?-3 long chain-PUFA) reduces inflammatory markers in various disorders. The goal of this research was to analyze the influence of ?-3 long chain-PUFA intake on gene expression and blood inflammatory markers in boys with DMD. Methods: In a placebo-controlled, double. Blind, randomized trial, boys with DMD (n = 36) consumed 2.9 g/day of ?-3 long chain-PUFA or sunflower oil as control, in capsules, for a period of 6 months. Blood was analyzed at baseline and at months 1, 2, 3, and 6 of supplementation for expression of inflammatory markers in leukocytes and serum. Results: There was high adherence to capsule intake (control: 95.3% ± 7.2%, and ?-3 long chain-PUFA: 97.4% ± 3.7% at month 6). Enrichment of EicosaPentaenoic Acid (EPA) and DocosaHexaenoic Acid (DHA) in erythrocytes increased significantly in patients supplemented with ?-3 long chain-PUFA compared with the placebo group during the 6 months of supplementation. Messenger RNA (mRNA) of the Nuclear Factor kappa beta (NF-?B) and its target genes InterLeukin 1 beta (IL-1ß) and IL-6 was downregulated significantly (p < 0.05) in leukocytes from DMD boys supplemented with ?-3 long chain-PUFA for 6 months, compared to the placebo group. Omega-3 long chain-PUFA intake decreased the serum IL-1ß (-59.5%; p = 0.011) and IL-6 (-54.8%; p = 0.041), and increased the serum IL-10 (99.9%, p < 0.005), in relation to those with placebo treatment. Conclusion: Supplementation with ?-3 long chain-PUFA 2.9 g/day is well-tolerated, has a beneficial reductive effect on proinflammatory markers, and increases an anti-inflammatory marker, indicating that ?-3 long chain-PUFA could have a potential therapeutic impact on chronic inflammation in DMD. This research is registered at clinicaltrials.gov (NCT018264229). © 2017 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism
Filiaciones:
Rodríguez-Cruz M.:
Laboratorio de Nutrición Molecular, Unidad de Investigación Médica en Nutrición, Hospital de Pediatría, Centro Médico Nacional Siglo XXI (CMN-SXXI), Instituto Mexicano del Seguro Social (IMSS), Mexico City, Mexico
Cruz-Guzmán O.D.R.:
Laboratorio de Nutrición Molecular, Unidad de Investigación Médica en Nutrición, Hospital de Pediatría, Centro Médico Nacional Siglo XXI (CMN-SXXI), Instituto Mexicano del Seguro Social (IMSS), Mexico City, Mexico
Almeida-Becerril T.:
Laboratorio de Nutrición Molecular, Unidad de Investigación Médica en Nutrición, Hospital de Pediatría, Centro Médico Nacional Siglo XXI (CMN-SXXI), Instituto Mexicano del Seguro Social (IMSS), Mexico City, Mexico
Solís-Serna A.D.:
Laboratorio de Nutrición Molecular, Unidad de Investigación Médica en Nutrición, Hospital de Pediatría, Centro Médico Nacional Siglo XXI (CMN-SXXI), Instituto Mexicano del Seguro Social (IMSS), Mexico City, Mexico
Atilano-Miguel S.:
Laboratorio de Nutrición Molecular, Unidad de Investigación Médica en Nutrición, Hospital de Pediatría, Centro Médico Nacional Siglo XXI (CMN-SXXI), Instituto Mexicano del Seguro Social (IMSS), Mexico City, Mexico
Sánchez-González J.R.:
Laboratorio de Nutrición Molecular, Unidad de Investigación Médica en Nutrición, Hospital de Pediatría, Centro Médico Nacional Siglo XXI (CMN-SXXI), Instituto Mexicano del Seguro Social (IMSS), Mexico City, Mexico
Barbosa-Cortés L.:
Laboratorio de Nutrición Molecular, Unidad de Investigación Médica en Nutrición, Hospital de Pediatría, Centro Médico Nacional Siglo XXI (CMN-SXXI), Instituto Mexicano del Seguro Social (IMSS), Mexico City, Mexico
Ruíz-Cruz E.D.:
Departamento de Genética, UMAE Hospital General “Dr. Gaudencio González Garza”, Centro Médico Nacional “La Raza”, IMSS, Mexico City, Mexico
Huicochea J.C.:
Departamento de Genética, Hospital de Pediatría, CMN-SXXI, IMSS, Mexico City, Mexico
Cárdenas-Conejo A.:
Departamento de Genética, Hospital de Pediatría, CMN-SXXI, IMSS, Mexico City, Mexico
Escobar-Cedillo R.E.:
Servicio de Electrodiagnóstico y Distrofia Muscular, Instituto Nacional de la Rehabilitación (INRehab), Mexico City, Mexico
Yam-Ontiveros C.A.:
Departamento de Genética, UMAE Hospital General “Dr. Gaudencio González Garza”, Centro Médico Nacional “La Raza”, IMSS, Mexico City, Mexico
Ricárdez-Marcial E.F.:
Departamento de Genética, UMAE Hospital General “Dr. Gaudencio González Garza”, Centro Médico Nacional “La Raza”, IMSS, Mexico City, Mexico
|